25 Apr 2016 07:00
Motif Bio plc
("Motif" or the "Company")
Analyst & Investor conference call
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that following the conference call for analysts and investors that took place on Wednesday 20 April 2016 a playback facility is available until Wednesday 4 May 2016. Dial-in details for the replay are below:
Please dial: | 0121 260 4861 (UK) |
| 1 866 268 1947 (US) +44 121 260 4861 (All other locations) |
Passcode: | 3110627 (followed by #) |
|
|
In call instructions |
|
Press 1 | Play Recording |
Press 2 | Stop Recording |
Press 4 | Rewind Recording |
Press 5 | Pause Recording |
Press 6 | Fast Forward Recording |
Press 0 | Repeat Instructions / Options Menu |
Questions were submitted to the Company via email following the call and these and their answers are available on the Company website: http://www.motifbio.com/conference-call-q-a/
For further information please contact:
Motif Bio plc Graham Lumsden (Chief Executive Officer)
| info@motifbio.com
|
Zeus Capital Limited (NOMAD & BROKER) Phil Walker/Dan Bate Dominic Wilson
| +44 (0)20 3829 5000 |
Northland Capital Partners Limited (BROKER) Patrick Claridge/ David Hignell John Howes/ Rob Rees (Broking)
| +44 (0)20 3861 6625 |
Walbrook PR Ltd. (FINANCIAL PR & IR) Paul McManus Mike Wort | +44 (0)20 7933 8780 or motifbio@walbrookpr.com Mob: +44 (0)7980 541 893 Mob: +44 (0)7900 608 002 |
|
|
MC Services AG (EUROPEAN IR) |
|
Raimund Gabriel | +49 (0)89 210 2280 |
Notes to Editors:
Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria. For additional information about Motif please visit www.motifbio.com.